SML3505

KP1339

≥98% (elemental analysis)

• Synonym(e): BOLD-100 without cesium, FFC14A sodium salt, IT-139, KP1019 sodium salt, IndazolH [trans-RuCl(4)-(Indazol)(2)] sodium salt, NKP1339, trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] sodium salt
• Empirische Formel (Hill-System): C₁₄H₁₂Cl₄N₄NaRu
• CAS-Nummer: 197723-00-5
• Molekulargewicht: 502.14
• MDL-Nummer: MFCD25976832
• UNSPSC-Code: 12352200
• NACRES: NA.77

Eigenschaften

• Qualitätsniveau: 100
• Assay: ≥98% (elemental analysis)
• Form: powder
• Farbe: , white to very dark grey
• Löslichkeit: H₂O: 2 mg/mL, clear (Warmed)
• Lagertemp.: -10 to -25°C
• SMILES String: Cl[Ru-](Cl)(Cl)Cl.C1(C=CC=C2)=C2NN=C1.C3(C=CC=C4)=C4NN=C3.[Na+]
• InChI: 1S/2C7H6N2.4ClH.Na.Ru/c2*1-2-4-7-6(3-1)5-8-9-7;;;;;;/h2*1-5H,(H,8,9);4*1H;;/q;;;;;;+1;+3/p-4
• InChIKey: WVVOCRYXBTVDRN-UHFFFAOYSA-J

Beschreibung

Biochem./physiol. Wirkung

KP1339 (KP1019 sodium) is a ruthenium-indazole complex-based anticancer agent that induces pronounced apoptosis in sensetive cancer cells (Capan1/HCT116/SW480/KB-3-1 IC50 by MTT assay = 44/50/145/170 µM) via ER homeostasis disruption and caspase 8 activation due to depletion of key cellular chaperones, including BiP/GRP78/HSPA5, in combination with enhanced protein damage. When administered in vivo, KP1339 exhibits anti-tumor efficacy in the murine SA-1 fibrosarcoma model (10.5, 21.0, 42.0 mg/150 µL/kg i.v.).

Ruthenium-indazole complex-based anticancer agent in cultures and in vivo via ER homeostasis disruption by depleting chaperones, including BiP/GRP78/HSPA5.

Sicherheitshinweise

• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable